Israel Englander’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.27M | Buy |
6,000
+3,300
| +122% | +$648K | ﹤0.01% | 4162 |
|
|
2026
Q1 | $529K | Sell |
2,700
-13,100
| -83% | -$2.55M | ﹤0.01% | 4740 |
|
|
2025
Q4 | $2.74M | Buy |
15,800
+13,800
| +690% | +$2.51M | ﹤0.01% | 3659 |
|
|
2025
Q3 | $381K | Buy |
2,000
+400
| +25% | +$71K | ﹤0.01% | 5230 |
|
|
2025
Q2 | $287K | Sell |
1,600
-9,800
| -86% | -$1.7M | ﹤0.01% | 5216 |
|
|
2025
Q1 | $1.93M | Sell |
11,400
-30,200
| -73% | -$4.96M | ﹤0.01% | 3815 |
|
|
2024
Q4 | $6.28M | Buy |
41,600
+36,700
| +749% | +$5.71M | ﹤0.01% | 2620 |
|
|
2024
Q3 | $761K | Sell |
4,900
-165,100
| -97% | -$24.7M | ﹤0.01% | 4486 |
|
|
2024
Q2 | $23.3M | Sell |
170,000
-245,700
| -59% | -$33.6M | 0.01% | 1362 |
|
|
2024
Q1 | $55.3M | Sell |
415,700
-117,900
| -22% | -$15.3M | 0.02% | 763 |
|
|
2023
Q4 | $73.6M | Buy |
533,600
+283,600
| +113% | +$37.3M | 0.03% | 559 |
|
|
2023
Q3 | $30.5M | Buy |
250,000
+225,000
| +900% | +$30M | 0.02% | 1075 |
|
|
2023
Q2 | $3.51M | Buy |
+25,000
| New | +$3.45M | ﹤0.01% | 2981 |
|
|
2023
Q1 | – | Sell |
-10,000
| Closed | -$1.56M | – | 6461 |
|
|
2022
Q4 | $1.56M | Sell |
10,000
-60,000
| -86% | -$8.62M | ﹤0.01% | 3763 |
|
|
2022
Q3 | $8.59M | Buy |
70,000
+20,000
| +40% | +$2.63M | 0.01% | 2333 |
|
|
2022
Q2 | $6.65M | Buy |
+50,000
| New | +$6.81M | ﹤0.01% | 2497 |
|
|
2022
Q1 | – | Sell |
-70,000
| Closed | -$12.1M | – | 7005 |
|
|
2021
Q4 | $12.1M | Sell |
70,000
-60,000
| -46% | -$9.13M | 0.01% | 1933 |
|
|
2021
Q3 | $18.9M | Buy |
130,000
+29,100
| +29% | +$4.26M | 0.01% | 1385 |
|
|
2021
Q2 | $13.3M | Buy |
100,900
+40,900
| +68% | +$5.35M | 0.01% | 1571 |
|
|
2021
Q1 | $7.7M | Buy |
60,000
+40,000
| +200% | +$4.93M | 0.01% | 2082 |
|
|
2020
Q4 | $2.38M | Buy |
20,000
+10,000
| +100% | +$1.22M | ﹤0.01% | 3104 |
|
|
2020
Q3 | $1.15K | Sell |
10,000
-20,000
| -67% | -$2.36M | ﹤0.01% | 3044 |
|
|
2020
Q2 | $3.42M | Buy |
+30,000
| New | +$3.18M | ﹤0.01% | 2109 |
|
|
2019
Q2 | – | Sell |
-210,000
| Closed | -$18.9M | – | 4112 |
|
|
2019
Q1 | $18.9M | Buy |
+210,000
| New | +$18.2M | 0.03% | 837 |
|
|
2018
Q1 | – | Sell |
-10,000
| Closed | -$985K | – | 3710 |
|
|
2017
Q4 | $985K | Buy |
+10,000
| New | +$948K | ﹤0.01% | 2711 |
|
|
2013
Q4 | – | Sell |
-38,800
| Closed | -$2.4M | – | 3506 |
|
|
2013
Q3 | $2.4M | Buy |
+38,800
| New | +$2.32M | 0.01% | 1569 |
|
Other funds holding DGX
EIG
Israel Englander's DGX Position: Q2 2026 in Review
Israel Englander reduced its Quest Diagnostics (DGX) stake by 77% in Q2 2026, selling an estimated $7.6M and leaving 11,434 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3660.
Israel Englander first reported a position in DGX in Q2 2013 and has held it in 48 quarters since. The position peaked at $130M in Q2 2024. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Israel Englander held 11,434 shares of Quest Diagnostics worth $2.42M as of Q2 2026.
- Israel Englander sold 38,732 Quest Diagnostics shares in Q2 2026, an estimated $7.6M.
- Quest Diagnostics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3660 holding.
- Israel Englander first reported a position in Quest Diagnostics in Q2 2013 and has held it in 48 quarters since.
- Israel Englander's Quest Diagnostics position peaked at $130M in Q2 2024.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.